| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 48.1MM | +9% |
| Gross Profit | 17.4MM | - |
| Cost Of Revenue | 30.7MM | +3% |
| Operating Income | -36.5MM | -15% |
| Operating Expenses | 53.9MM | - |
| Net Income | -37.4MM | -14% |
| R&D | 17.1MM | -6% |
| G&A | 36.8MM | -6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SEATTLE, February 09, 2024--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the Company has entered into a credit agreement with its existing lenders comprised of (a) $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S. Bankruptcy court approving the credit facility, and (b) an additional $35,000,000 in new money term lo
The life science tools company said it is evaluating whether to sell all or part of its business after attracting interest from potential buyers.
SEATTLE, February 05, 2024--NanoString Technologies, Inc. (NASDAQ: NSTG) ("NanoString" or "the Company"), a leading provider of life science tools for discovery and translational research, today announced that steps are being taken to protect its business, customers, employees and its mission to "Map the Universe of Biology." With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy
SEATTLE, February 01, 2024--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry’s first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), Na
SEATTLE, January 07, 2024--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the release of the first public dataset of the whole transcriptome obtained at true single-cell resolution on the CosMx™ Spatial Molecular Imager (SMI). The data will be highlighted at the 42nd annual J.P. Morgan Healthcare Conference 2024 in San Francisco during NanoString’s corporate presentation on Wednesday, January 10, 20
SEATTLE, January 05, 2024--NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees.
SEATTLE, January 04, 2024--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd annual J.P. Morgan healthcare conference, being held January 8-11, 2024.
Playing in the field of nano-cap stocks is similar to the concept of stealing bases. In a tight baseball game, every advantage counts. Therefore, you might get the signal from the manager to steal a bag. You could end up being the hero or end up looking like a fool. It’s a binary proposition: high risk, high reward. And while advantages help break up a tight game, you also don’t want to give up cheap outs. That could put you in a serious disadvantage. And that’s why people seldom invest heavily
SEATTLE, November 19, 2023--NanoString Comments on Delaware District Court Verdict
Conestoga Capital Advisors, an asset management company, released its “Micro Cap Strategy” third-quarter 2023 investor letter. A copy of the same can be downloaded here. The micro capitalization segment of the market proved the most challenging in the quarter with the Russell Micro Cap Index declining -7.93%. The Russell Micro Cap Growth Index fell further with a […]